Researchers at the UNC-Chapel Hill and North Carolina State University have uncovered a novel approach to creating inhalable vaccines using nanoparticles that shows promise for targeting lung-specific diseases, such as influenza, pneumonia and tuberculosis. The work was led by Cathy Fromen and Gregory Robbins, members of the DeSimone and Ting labs at UNC Lineberger, and reveals that a particle’s surface charge plays a key role in eliciting immune responses in the lung.
